论文部分内容阅读
目的探讨药物治疗和PCI治疗非ST段抬高型心肌梗死患者的预后情况。方法选择2009年1月—2014年12月台州市第一人民医院心血管内科非ST段抬高型心肌梗死药物治疗患者623例和药物治疗+PCI治疗患者412例作为研究对象。观察药物治疗组和药物治疗+PCI治疗组的终点事件发生率和中位生存时间,药物治疗组和药物治疗+PCI治疗组不同TIMI评分和不同年龄的终点事件发生率。结果药物治疗组的主要终点事件和次要终点事件的发生率均高于药物治疗+PCI治疗组(P<0.05)。药物治疗组的主要终点事件及次要终点事件的中位生存时间均低于药物治疗+PCI治疗组(P<0.05)。药物治疗组和药物治疗+PCI组TIMI评分0~2分者的主要终点事件和次要终点事件的发生率比较差异没有统计学意义(P>0.05),药物治疗组TIMI评分3~5分和6~7分主要终点事件及次要终点事件的发生率均高于药物治疗+PCI组(P<0.05)。药物治疗组的<65岁患者主要终点事件及次要终点事件的发生率和药物治疗+PCI组比较差异没有统计学意义(P>0.05),药物治疗组的65~75岁及>75岁患者主要终点事件及次要终点事件的发生率均高于药物治疗+PCI组(P<0.05)。结论 PCI治疗能够降低非ST段抬高型心肌梗死不良终点事件的发生率,延长中位生存时间,对TIMI分级中高危患者及年龄>65岁的患者进行PCI介入治疗能够有效改善其预后。
Objective To investigate the prognosis of patients with non-ST-elevation myocardial infarction treated with drugs and PCI. Methods A total of 623 patients with non-ST-segment elevation myocardial infarction and 612 patients treated with PCI were enrolled in the First People’s Hospital of Taizhou from January 2009 to December 2014. The incidence and the median survival time of drug-treated group and drug-treated + PCI group were observed. The TIMI score and the incidence of end-point events of different ages in the drug-treated group and the drug-treated + PCI group were observed. Results The incidence of primary end points and secondary end points in the drug-treated group was higher than that in the drug-treated + PCI group (P <0.05). Median survival time of the primary endpoint and secondary endpoint in the drug-treated group were lower than those in the drug-treated + PCI group (P <0.05). There was no significant difference in the incidence of primary end point and secondary end point between the drug treatment group and the drug treatment + PCI group with TIMI score of 0 ~ 2 (P> 0.05). The TIMI score of the drug treatment group was 3 ~ 5 and The incidence of primary endpoints and secondary endpoints were significantly higher in patients 6-7 than those in medication + PCI group (P <0.05). The incidence of primary end point and secondary end point events in the drug-treated group <65 years of age was significantly different from that in the drug-treated + PCI group (P> 0.05). Patients in the drug-treated group aged 65-75 years and> 75 years The incidence of primary end points and secondary end points were higher than those in the drug-treated + PCI group (P <0.05). Conclusion PCI can reduce the incidence of adverse end-point events and prolong the median survival time in patients with non-ST-segment elevation myocardial infarction. PCI can improve the prognosis of high-risk TIMI patients and patients aged> 65 years with PCI.